Fusion Antibodies Plc (GB:FAB) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Fusion Antibodies Plc has reported a substantial growth in revenues, reaching £1.2 million for the first half of FY2025, more than doubling from the previous year. This financial improvement is complemented by a significant reduction in losses, positioning the company well for future profitability. The company has also secured new contracts and expanded collaborations, showcasing its robust growth strategy in the antibody discovery sector.
For further insights into GB:FAB stock, check out TipRanks’ Stock Analysis page.